

Table S1. Peptides and peptidomimetics approved by the FDA between 2017 and 2023.

Year approved	Total drugs	Total peptides	Peptides/ peptidomimetics	
2017	46	6	Etelcalcetide	Linear
			Semaglutide	Linear
			Abaloparatide	Linear
			Macimorelin	Linear
			Plecanatide	Cyclic
			Angiotensin II	Linear
2018	59	1	Lutetium ¹⁷⁷ Lu-DOTA-TATE	Cyclic
2019	48	3	Bremelanotide	Cyclic
			Afamelanotide	Linear
			Edotreotide gallium ⁶⁸ Ga	Cyclic
2020	53	3	Setmelanotide	Cyclic
			Cu-DOTATE	Cyclic
			⁶⁸ Ga PSMA-1	Linear
2021	51	8	Vosoritide	Cyclic
			Odevixibat	Linear
			Melphalan flufenamide	Linear
			Dasiglucagon	Linear
			Difelikefalin	Linear
			Piflufolastat- ¹⁸ F	Linear
			Pegcetacoplan	Cyclic
			Voclosporin	Cyclic
2022	37	3	Lutetium vipivotide tetraxetan	Linear
			Tirzepatide	Linear
			Terlipressin	Cyclic
2023	55	6	Zilucoplan	Cyclic
			Motixafortide	Cyclic
			Flotufolastat ¹⁸ F	Linear
			Nirmatrelvir, ritonavir	Linear
			Rezafungin	Cyclic
			Trofnetide	Linear
Total drugs approved by the FDA (2017-2023)				349
Total peptides and peptidomimetics approved by the FDA (2017-2023)				30
Percentage of peptides/ peptidomimetics approved by the FDA (2017-2023)				9%